Letters, Testimony & Comments

Hearing Testimony Scott Koenig, M.D., PH.D. Before the House of Representatives Committee on Small Business Good morning Chairman...
April 7 2011
On behalf of the Biotechnology Industry Organization (BIO) and its more than 1,100 member companies, academic institutions, state...
March 24 2011
Dear Ms. Blue: The Biotechnology Industry Organization (BIO) is submitting this letter in response to the request by the United States...
November 1 2009
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
November 15 2008
The letter, signed by approximately 60 patient groups, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
September 18 2008
BIO addresses concerns to FASB’s Staff Position on accounting for instrument C and conventional convertible debt.
October 27 2007
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed...
July 26 2005
To Hector Barreto, Administrator, U.S. Small Business Administration
November 4 2003
To Hector Barreto, Administrator, U.S. Small Business Administration
October 21 2003
Administrator, U.S. Small Business Administration
May 13 2003
Part D-Small Business Early-Stage Investment Program Sec. 399A Establishment of Program The Administrator shall establish and carry...
September 13 2011
These written comments were submitted to accompany the testimony of BIO's Interim Vice President for State Government Relations Pete Pellerito in support of legislative and regulatory environments that benefit biosciences industry job growth.
April 7 2011
The House Subcommittee on Healthcare and Technology held a hearing on The Creating Jobs Through Small Business Innovation Act of 2011, a bill that would reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which help fund small innovative companies on the brink of new technologies and discoveries.
March 24 2011
BIO submitted letters of support for the American Research and Competitiveness Act of 2011 (HR 942) to the lead House of Representatives sponsors.
November 1 2009
BIO is submitting this letter in response to the request by the United States Trade Representative (USTR) for comments to compile the National Trade Estimate (NTE) Report on Foreign Trade Barriers.
November 15 2008
BIO urges that changes to FIN46(R) accurately reflect the underlying economics of collaborations.
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
January 23 2014
BIO announced plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 16th annual BIO CEO & Investor Conference.
November 13 2013
The Bill will spur capital formation for small public companies
September 30 2013
NSF-funded companies focused on drug discovery, diagnostics and other platform technologies.
September 11 2013
Speakers will provide fresh insight, investment opportunities in biotech sector.